title: Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling.
abstract: It is today indisputable that great progresses have been made in our molecular understanding of cancer cells, but an effective implementation of such knowledge into dramatic cancer-cures is still belated and yet desperately needed. This review gives a snapshot at where we stand today in this search for cancer understanding and definitive treatments, how far we have progressed and what are the major obstacles we will have to overcome both technologically and for disease modelling. In the first part, promising 3rd/4th Generation Sequencing Technologies will be summarized (particularly IonTorrent and OxfordNanopore technologies). Cancer modelling will be then reviewed from its origin in XIX Century Germany to today's NGS applications for cancer understanding and therapeutic interventions. Developments after Molecular Biology revolution (1953) are discussed as successions of three phases. The first, PH1, labelled "Clonal Outgrowth" (from 1960s to mid 1980s) was characterized by discoveries in cytogenetics (Nowell, Rowley) and viral oncology (Dulbecco, Bishop, Varmus), which demonstrated clonality. Treatments were consequently dominated by a "cytotoxic eradication" strategy with chemotherapeutic agents. In PH2, (from the mid 1980s to our days) the description of cancer as "Gene Networks" led to targeted-gene-therapies (TGTs). TGTs are the focus of Section 3: in view of their apparent failing (Ephemeral Therapies), alternative strategies will be discussed in review part II (particularly cancer immunotherapy, CIT). Additional Pitfalls impinge on the concepts of tumour heterogeneity (inter/intra; ITH). The described pitfalls set the basis for a new phase, PH3, which is called "NGS Era" and will be also discussed with ten emerging cancer models in the Review 2nd part.
authors.affiliation: University of Pisa Medical School, Oncology Department, via Roma 55, 56127 Pisa, Italy. Electronic address: profrovigatti@gmail.com.
authors.forename: Ugo
authors.initials: U
authors.lastname: Rovigatti
mesh_terms: D057166:High-Throughput Screening Assays / Q000266:history* / Q000379:methods*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009369:Neoplasms / Q000266:history*
keywords: ALK+NSCLC; Cancer modelling history; Chronic myelogenous leukaemia (CML); Crizotinib; Cytoxic chemotherapy; Erlotinib; Gefitinib; Gene networks; IDH mutations; Imatinib; Inter-tumour heterogeneity; Intra-tumour heterogeneity; Ion torrent; Melanoma; Nanopore; Next generation sequencing (NGS); Non small cell lung carcinoma (NSCLC); Targeted gene therapy (TGT); Tumour clonality; Vemurafenib